Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19), hepatitis B Virus (HBV) and human metapneumovirus (hMPV).

Learn More »

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

September 22, 2022
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
September 7, 2022
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

Upcoming Events

More events are coming soon.